Drug Type Therapeutic radiopharmaceuticals |
Synonyms Astatine-211-Parthanatine, At211-Parthanatine, [211At]-PTT + [1] |
Target |
Action inhibitors |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neuroblastoma | Preclinical | United States | 17 Nov 2022 | |
| Glioblastoma | Preclinical | United States | - | |
| Ovarian Diseases | Preclinical | United States | - |





